Value of Cardiac Rehabilitation on the Treatment of Cardiovascular Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-01

Study Completion Date

2025-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cardiac rehabilitation is a valuable treatment for patients with a broad spectrum of cardiac disease. Current guidelines support its use in patients after acute coronary syndrome, coronary artery bypass grafting, coronary stent placement, valve surgery, and stable chronic systolic heart failure. Its use in these conditions is supported by a robust body of research demonstrating improved clinical outcomes. Despite this evidence, cardiac rehabilitation referral and attendance remains low and interventions to increase its use need to be developed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Rehabilitation Therapy on Patients After Acute Myocardial Infarction

NCT00725088

Acute Myocardial Infarction

UNKNOWN NA

A New Cardiac Rehabilitation Treatment in the Application of Ischemic Heart Disease

NCT06681506

Ischemic Heart Disease Cardiac Rehabilitation

RECRUITING NA

Phase One Cardiac Rehabilitation Outcomes Post Valve Replacement Surgery

NCT07205393

Valve Replacement Surgery

RECRUITING NA

Early Initiation of Post Sternotomy CArdiac Rehabilitation

NCT03223558

Coronary Artery Disease Aortic Valve Disease Mitral Valve Disease

COMPLETED NA

Cardiac Rehabilitation and Coronary Artery Disease

NCT06579807

Coronary Artery Disease Atherosclerosis

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The trial was conducted in Shenzhen in China. This study will recruit 100 patients with cardiovascular disease with a median and minimum follow-up of 24 and 6 months. Patients will be individually randomized to receive either a cardiac rehabilitation program (n = 50) or enhanced standard care involving educational advice (n = 50). The co-primary outcomes are: 1) first occurrence of major adverse cardiovascular events (MACE) (composite of all-cause mortality, myocardial infarction, stroke, or emergency cardiovascular hospitalization); and 2) self-rated health on the Quality of Life-5 Dimensions-5 Level visual analogue scale.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Rehabilitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment group

the patients treated with cardiac rehabilitation intervention.

Group Type EXPERIMENTAL

cardiac rehabilitation

Intervention Type BEHAVIORAL

Cardiac rehabilitation is a valuable treatment for patients with a broad spectrum of cardiac disease.

Control group

the patients treated without cardiac rehabilitation intervention.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cardiac rehabilitation

Cardiac rehabilitation is a valuable treatment for patients with a broad spectrum of cardiac disease.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cardiovascular disease

Exclusion Criteria

* Incalculable TFC
* Coronary artery spasm or ectasia
* LV ejection fraction \< 52% in males or \< 54% in females
* Abnormal heart structure (congenital heart disease, cardiomyopathies, or valvular dysfunction)
* Pericardial disease (pericardial effusion or constrictive pericarditis)
* Previous history of myocardial infarction
* Uncontrolled hypertension (systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 105 mmHg)
* Hyperthyroidism
* Hypothyroidism
* Malignancy
* Autoimmune disease
* Infection
* Pulmonary, hepatic, and renal disorders
* Haematological disorders (anaemia, bone marrow involved by neoplastic disease, or red blood cell transfusions)

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes